What is the armodafinil dosage?

Tablet strengths and labelled doses
ItemLabel
Tablet strengths50, 150, 200 and 250 mg1
Obstructive sleep apnea or narcolepsy150 mg to 250 mg orally once a day as a single dose in the morning1
Shift work disorder150 mg orally once a day, approximately 1 hour before the work shift1

The Nuvigil label gives 150 mg to 250 mg once a day in the morning for sleep apnea or narcolepsy and 150 mg once a day about 1 hour before the work shift for shift work disorder.1

Tablet strengths and labelled doses

The table is set at the top of the page

The label names 250 mg/day as the maximum recommended human dose.1 In sleep apnea it says doses up to 250 mg/day, given as a single dose, were well tolerated, with no consistent evidence of added benefit over 150 mg/day.1 For severe hepatic impairment the label calls for a reduced dosage, and for geriatric patients it asks that lower doses and close monitoring be considered.1 It gives no number for either.

What the trials used

TrialDose and schedulePeopleLength
Roth 2006, sleep apnea150 mg/d or 250 mg/d or placebo, once daily2395 nCPAP-adherent adults with residual sleepiness: 133, 131 and 131 per arm212 weeks2
Harsh 2006, narcolepsy150 mg, 250 mg or placebo, once daily3196 adults: 65, 67 and 64 per arm312 weeks3
Czeisler 2009, shift work disorder150 mg or placebo, 30 to 60 minutes before each night shift4254 night-shift workers412 weeks4

In Darwish 2010, an open-label crossover pharmacokinetic study in 42 patients with treated sleep apnea, multiple-dose armodafinil was 100 mg once daily on days 1 and 2, then 200 mg once daily on days 3 through 10.5

How armodafinil is taken

The label's dose is taken orally once a day: as a single dose in the morning for sleep apnea or narcolepsy, and about 1 hour before the work shift for shift work disorder.1 The Medication Guide says Nuvigil too close to bedtime may make it harder to go to sleep.1 Peak levels come about 2 hours after a fasted dose, and food may delay this by 2-4 hours.1 Steady state is reached within 7 days, at 1.8 times the exposure after a single dose.1 Darwish 2009, a pooled analysis of three single-dose studies in healthy adults, found a mean terminal half-life of about 13 hours for armodafinil.6 In Darwish 2010, in 42 patients with treated sleep apnea, the mean half-life of armodafinil was 16.5 (SD 4.44) hours.5

Storage

The label says to store tablets at 20o - 25o C (68o - 77o F).1

Mixing, syringe marks and logged use

The Nuvigil label lists armodafinil only as tablets, so there is no concentration, water volume or syringe mark to work out.1 Too few people logged armodafinil in Milligram for a share to be printed at the 50-person floor.

Frequently asked questions

Can you take armodafinil with food?

The Medication Guide says Nuvigil can be taken with or without food.1

Is there a 50 mg armodafinil dose?

50 mg is a tablet strength; the pack found no labelled 50 mg dose.1 In NCT01305408, an 8-week trial of armodafinil added to mood stabilizers in 399 adults with bipolar I depression, dosing started at 50 mg/day and rose in steps of 50 mg/day to 150 mg/day.7

Is armodafinil labelled for ADHD or studying?

The label's indication is excessive sleepiness in adults with sleep apnea, narcolepsy or shift work disorder, and it lists no other condition.1 A review of armodafinil for adult ADHD says trials are still needed before it can be a therapeutic alternative.8 The pack found no armodafinil ADHD trial and no student trial. The same 2024 review reports several studies in healthy adult men in which armodafinil 250 mg improved alertness during sleep deprivation compared with placebo.8

Does armodafinil have cycles or breaks?

The label has no cycling advice and says abrupt cessation or dose reduction after chronic use can cause withdrawal symptoms.1

References

  1. Cephalon, LLC (DailyMed). These highlights do not include all the information needed to use NUVIGIL safely and effectively. See full prescribing information for NUVIGIL. NUVIGIL ® (armodafinil) tablets, for oral use, C-IV Initial U.S. Approval: 2007. 2022. dailymed.nlm.nih.gov
  2. PubMed. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. 2006. pubmed.ncbi.nlm.nih.gov
  3. PubMed. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. 2006. pubmed.ncbi.nlm.nih.gov
  4. PMC. Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study. pmc.ncbi.nlm.nih.gov
  5. PubMed. Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study. 2010. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. 2009. pubmed.ncbi.nlm.nih.gov
  7. ClinicalTrials.gov. NCT01305408: Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder. 2015. clinicaltrials.gov
  8. PMC. Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review. 2024. pmc.ncbi.nlm.nih.gov